Stock Events

Stock Events

GH Research 

€13.6
0
+€0.4+3.03% Friday 09:20

Statistics

Day High
13.6
Day Low
13.6
52W High
16.3
52W Low
8
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q4 2025
Next
-0.25
-0.23
-0.21
-0.2
Expected EPS
-0.24744498405999998
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1KA.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap712.95M
Compass Pathways operates in the psychedelic medicine space, focusing on psilocybin therapy for depression, directly competing with GH Research's focus on mental health treatments.
AtaiBeckley
ATAI
Mkt Cap1.33B
ATAI Life Sciences is a biotech company with a focus on psychedelic and non-psychedelic compounds for mental health disorders, competing in the same space as GH Research.
Nuveen Municipal Income
NUMI
Mkt Cap0
Numinus Wellness focuses on psychedelic production and therapy, including mental health treatments, positioning it as a competitor to GH Research.
Revive Therapeutics
RVVTF
Mkt Cap12.63M
Revive Therapeutics explores the use of psychedelics in treatments, including mental health, which competes with GH Research's therapeutic focus.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson, through its subsidiary Janssen Pharmaceuticals, has developed a ketamine-based treatment for depression, competing in the mental health treatment space with GH Research.

About

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Show more...
CEO
Mr. Florian Schonharting M.Sc. (Econ)
Employees
73
Country
Ireland
ISIN
IE000GID8VI0

Listings

STU
DE
1KA.STU
F
DE
1KA.F
MU
DE
1KA.MU
XNAS
US
GHRS

0 Comments

Share your thoughts

FAQ

What is GH Research stock price today?▼
The current price of 1KA.MU is €13.6 EUR — it has increased by +3.03% in the past 24 hours. Watch GH Research stock price performance more closely on the chart.
What is GH Research stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange GH Research stocks are traded under the ticker 1KA.MU.
Is GH Research stock price growing?▼
1KA.MU stock has risen by +9.68% compared to the previous week, the month change is a +2.26% rise, over the last year GH Research has showed a +66.87% increase.
When is the next GH Research earnings date?▼
GH Research is going to release the next earnings report on May 07, 2026.
What were GH Research earnings last quarter?▼
1KA.MU earnings for the last quarter are -0.2 EUR per share, whereas the estimation was -0.23 EUR resulting in a +13.03% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does GH Research have?▼
As of April 13, 2026, the company has 73 employees.
In which sector is GH Research located?▼
GH Research operates in the Health & Wellness sector.
When did GH Research complete a stock split?▼
GH Research has not had any recent stock splits.
Where is GH Research headquartered?▼
GH Research is headquartered in Dublin, Ireland.